Hale Basak Caglar
Hale Basak Caglar has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Aaron M. Allen
Institute of Oncology, Davidoff Center, Rabin Medical Center, Petah Tikva, Israel
1 shared publication - Alkim Aydin1 shared publication
Alptekin Arifoglu
Radiation Oncology Department Acıbadem Altunizade Hospital Istanbul Turkey
1 shared publication- Ayşe Nur DEMİRAL
Department of Radiation Oncology Dokuz Eylül University Faculty of Medicine Izmir Türkiye
1 shared publication - Banu Atalar
Department of Radiation Oncology, Acıbadem University Medical Faculty, Maslak Hospital, Istanbul, Turkiye
1 shared publication - Bilgehan Sahin
Department of Radiation Oncology, Acibadem Mehmet Ali Aydinlar University, School of Medicine, Istanbul, Turkey
1 shared publication
Latest Publications
- Open Access
- 29 November 2024
- Published by Elsevier in Materials & Design
- Vol. 248
Dual-laser powder bed fusion using 450 nm diode area melting and 1064 nm galvo-scanning fiber laser sources
- 29 November 2024
- Published by Elsevier in Materials & Design
- Vol. 248
Open AccessDual-laser powder bed fusion using 450 nm diode area melting and 1064 nm galvo-scanning fiber laser sources
- 4 August 2020
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 14 (11) , 1050-1059
Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study
Objective We identified factors influencing outcomes in patients with medically inoperable early‐stage lung cancer (MIESLC) treated with stereotactic ablative radiation therapy (SABR) at 14 centers in Turkey. Methods We retrospectively analyzed 431 patients with stage I‐II MIESLC treated with SABR from 2009 through 2017. Age; sex; performance score; imaging technique; tumor histology and size; disease stage radiation dose, fraction, and biologically effective dose with an α/β ratio of 10 (BED10); tumor location; and treatment center were evaluated for associations with overall survival (OS), local control (LC), and toxicity. Results Median follow‐up time was 27 months (range 1–115); median SABR dose was 54Gy (range 30–70) given in a median 3 fractions (range 1–10); median BED10 was151 Gy (range 48–180). Tumors were peripheral in 285 patients (66.1%), central in 69 (16%), and 100Gy (p =0.011), adenocarcinoma (p =0.025), and complete response on first evaluation (p =0.007) predicted favorable LC. BED10>120Gy (hazard ratio [HR] 1.9, 95% confidence interval [CI] 1.1–3.2,p =0.019) and tumor size (p =0.003) predicted favorable OS. No grade 4‐5 acute side effects were observed; late effects were grade ≤3 pneumonitis (18 [4.2%]), chest wall pain (11 [2.5%]), and rib fracture (1 [0.2%]). Conclusion SABR produced encouraging results, with satisfactory LC and OS and minimal toxicity. BED10>120 Gy was needed for better LC and OS for large, non‐adenocarcinoma tumors.
- 4 August 2020
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 14 (11) , 1050-1059
Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study
Objective We identified factors influencing outcomes in patients with medically inoperable early‐stage lung cancer (MIESLC) treated with stereotactic ablative radiation therapy (SABR) at 14 centers in Turkey. Methods We retrospectively analyzed 431 patients with stage I‐II MIESLC treated with SABR from 2009 through 2017. Age; sex; performance score; imaging technique; tumor histology and size; disease stage radiation dose, fraction, and biologically effective dose with an α/β ratio of 10 (BED10); tumor location; and treatment center were evaluated for associations with overall survival (OS), local control (LC), and toxicity. Results Median follow‐up time was 27 months (range 1–115); median SABR dose was 54Gy (range 30–70) given in a median 3 fractions (range 1–10); median BED10 was151 Gy (range 48–180). Tumors were peripheral in 285 patients (66.1%), central in 69 (16%), and 100Gy (p =0.011), adenocarcinoma (p =0.025), and complete response on first evaluation (p =0.007) predicted favorable LC. BED10>120Gy (hazard ratio [HR] 1.9, 95% confidence interval [CI] 1.1–3.2,p =0.019) and tumor size (p =0.003) predicted favorable OS. No grade 4‐5 acute side effects were observed; late effects were grade ≤3 pneumonitis (18 [4.2%]), chest wall pain (11 [2.5%]), and rib fracture (1 [0.2%]). Conclusion SABR produced encouraging results, with satisfactory LC and OS and minimal toxicity. BED10>120 Gy was needed for better LC and OS for large, non‐adenocarcinoma tumors.
- Open Access
- 1 September 2008
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 72 (1) , S626
Hyperpolarized Helium MRI and the Importance of Ventilation Tumor Volumes (VTVs) before and after RT for Non-small Cell Lung Cancer
- 1 September 2008
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 72 (1) , S626
Open AccessHyperpolarized Helium MRI and the Importance of Ventilation Tumor Volumes (VTVs) before and after RT for Non-small Cell Lung Cancer